|
UA103895C2
|
|
Glucokinase activators
|
|
US2008216736A1
|
|
Microfluidic device with diffusion between adjacent lumens
|
|
TW200911757A
|
|
Crystalline forms of histone deacetylase inhibitors
|
|
EP2091947A2
|
|
Glucokinase activators
|
|
CN101573335A
|
|
Kinase inhibitors
|
|
CA2666130A1
|
|
Kinase inhibitors
|
|
US2007281942A1
|
|
Substituted indazoles as glucokinase activators
|
|
US2007213349A1
|
|
Glucokinase activators
|
|
EP1948614A2
|
|
Glucokinase activators
|
|
WO2006105127A2
|
|
Hydroxysteroid dehydrogenase inhibitors
|
|
US7534592B1
|
|
Crystallization of carboxyltransferase domain of Acetyl-CoEnzyme A Carboxylase 2 with a ligand
|
|
EP1888544A2
|
|
Hydroxysteroid dehydrogenase inhibitors
|
|
EP1824831A2
|
|
Histone deacetylase inhibitors
|
|
EP1778669A2
|
|
Kinase inhibitors
|
|
WO2005105788A1
|
|
Indole derivatives and use thereof as kinase inhibitors
|
|
US7368269B1
|
|
Crystallization of MAPK/ERK Kinase 2
|
|
EP1694686A1
|
|
Kinase inhibitors
|
|
US7416710B1
|
|
Method and system for performing crystallization trials
|
|
US7270987B1
|
|
Crystallization of FMS-like tyrosine kinase 3
|
|
US7241868B1
|
|
Crystallization of Glucocorticoid Receptor
|
